Sign in
CompletedPhase 3

Hydrocorticose and vasopressin in post-resuscitation syndrome

Key facts

Who runs it
Assistance Publique Hopitaux De Paris
Where
France17 sites in 1 countryChoose a country to see its sites
Status
Completed
Phase
Phase 3
People taking part
380 people enrolled
Started
18 Jul 2021
Ended
5 Aug 2025
Type of study
Interventional
Record updated
28 April 2025

Who can take part

Age
18 years and older
Sex
Women and men
Healthy volunteers
Cannot take part
Show the full registry criteria (19)Hide the full registry criteria

Who can take part

  • Adult patients (≥18y)
  • Cardiac arrest (in-hospital or out-of-hospital) with sustained ROSC (> 30 minutes) admitted to the ICU
  • Post-resuscitation shock defined as arterial hypotension (SAP < 90 mmHg or MAP < 65 mmHg) unresponsive to adequate fluid loading, which occurred within the first 24 hours after ROSC and requiring norepinephrine tartrate/epinephrine continuous infusion at a dose greater or equal to 0.2μg/kg/min for at least 3 hours
  • A maximal delay between the start of norepinephrine infusion and randomization of 9 hours
  • Informed written consent of a legally authorized close relative, or emergency procedure

Who cannot take part

  • inclusion in another randomized trial involving a drug that could interact with either interventional drug
  • Previously known adrenal insufficiency
  • Limitation of life-sustaining therapies
  • Ongoing treatment by any steroids, at a daily dose greater or equal to 7.5mg/d equivalent prednisone for at least 3 weeks
  • Evidence for a traumatic or a neurological cause of cardiac arrest
  • Hypersensitivity to argipressin and to its excipients
  • Hypersensitivity to hydrocortisone and to its excipients
  • In-ICU cardiac arrest
  • Shock due to uncontrolled haemorrhage
  • Gastrointestinal bleeding in the past 6 weeks
  • Legal protection (i.e. incompetence to provide consent, guardianship, curator or incarceration)
  • No affiliation with the French health care system
  • Ongoing extra-corporeal circulatory assistance
  • Pregnant or breastfeeding women

Where is this trial?

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

to demonstrate the superiority of AVP and hydrocortisone compared with placebo regarding day-30 survival and neurological recovery in post-cardiac arrest patients with hemodynamic failure.

Data and sources

Registry record
Listed on ClinicalTrials.gov and on the EU's official list of trials (CTIS).How to verify a trial in the registry
Official title
HYVAPRESS. HYdrocortisone and VAsopressine in Post-RESuscitation Syndrome
Publications
Record updated
28 April 2025